SCHEDULE 13G: Long Focus Capital Group Discloses Significant Passive Stake in Aura Biosciences, Inc.

A group of entities and individuals, including Long Focus Capital Management, LLC and John Helmers, have disclosed a passive ownership stake in Aura Biosciences, Inc., with John Helmers beneficially owning 5.7% of the common stock.

Summary

• Long Focus Capital Management, LLC, Long Focus Capital Master, LTD., Condagua, LLC, John Helmers, and Glenn Helmers have filed a Schedule 13G regarding their beneficial ownership in Aura Biosciences, Inc. common stock.
• The filing indicates that John Helmers beneficially owns 2,507,774 shares of Aura Biosciences, Inc. common stock, representing 5.7% of the class.
• Long Focus Capital Management, LLC reports beneficial ownership of 2,507,774 shares, representing 3.6% of the class, with shared voting and dispositive power.
• Long Focus Capital Master, LTD. reports beneficial ownership of 1,782,997 shares, representing 3.6% of the class, with shared voting and dispositive power.
• Condagua, LLC reports beneficial ownership of 724,777 shares, representing 1.4% of the class, with shared voting and dispositive power.
• Glenn Helmers reports beneficial ownership of 724,777 shares, representing 1.4% of the class.
• The filing is made under Rule 13d-1(c), signifying a passive investment without intent to influence control of the issuer.
• The event requiring this filing occurred on December 24, 2024, and the statement was signed on January 3, 2025.

Sentiment

Score: 5

Explanation: Neutral, as this is a standard regulatory disclosure of passive ownership and does not contain performance or strategic updates about the issuer.

Positives

• Disclosure of a significant passive investment by a group of entities and individuals, including Long Focus Capital, indicating investor interest in Aura Biosciences, Inc.

Risks

• The reporting persons have certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of Aura Biosciences, Inc.

Future Outlook

The document is a beneficial ownership disclosure and does not contain any forward-looking statements or guidance regarding Aura Biosciences, Inc.'s future performance or operations.

Industry Context

This filing is a standard regulatory disclosure of a passive ownership stake and does not provide specific insights into broader industry trends or competitive landscape for Aura Biosciences, Inc.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant passive ownership stakes, potentially signaling confidence from institutional investors in Aura Biosciences, Inc.

Next Steps

• The reporting persons are responsible for timely filing of subsequent amendments to this Schedule 13G if there are changes to their beneficial ownership or intent.

Key Dates

Keywords

Aura Biosciences, Long Focus Capital, Schedule 13G, Beneficial Ownership, Passive Investment, SEC Filing, Common Stock